The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.
Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.
LSX World Congress USA brings life sciences investment and partnering to Boston.
While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.
Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.
The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.
3D-printed organs and tissues are now a reality, but questions remain over their patentability, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
While registering trademarks for cannabis products at the USPTO is currently impossible, brands are applying creative solutions to the problem, says Leon Steinberg of Dennemeyer.
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.